Proactive Investors - Run By Investors For Investors

CytoDyn announces two new additions to management team

The company named Brendan Rae as senior vice president of business development and George Bitar as executive director, head of quality
lab work
The new hires come as CytoDyn seeks FDA approval of its flagship drug leronlimab to treat cancer and HIV

CytoDyn Inc. (OTCMKST:CYDY) announced Tuesday two new additions to its management team as it seeks regulatory approval of its flagship drug leronlimab (PRO 140) to treat cancer and HIV.

The Vancouver, Washington-based biotech company said in a statement that it has named Brendan Rae as senior vice president of Business Development and George Bitar as executive director, head of quality.

News of the appointments comes as the Food and Drug Administration has granted fast-track status to leronlimab for use in combination with carboplatin for the treatment of patients with triple negative breast cancer (mTNBC).

The FDA also has fast-tracked leronlimab in combination with HAART, or highly active antiretroviral therapy, for HIV treatment. And CytoDyn on Monday announced that it would test the drug to prevent fatty liver disease in mice.

READ: CytoDyn's flagship drug leronlimab to be tested to prevent fatty liver diease in mice

Given the potential of leronimab, CEO Nader Pourhassan said the “timing is ideal to have Brendan’s and George’s deep experience on the team, as we implement our commercialization plan and pursue new potential strategic agreements.”

Rae will lead CytoDyn’s business development initiatives, including all potential partnering and licensing opportunities for leronlimab, the company said, which added that Rae is an accomplished licensing and business development executive with a proven track record of deal-making. 

Rae comes to CytoDyn from Serina Therapeutics, a private company, where he was chief business officer, responsible for partnering, out licensing and overall company strategy. Previously, Rae was the executive director of NPS Pharmaceuticals and head of GI and Endocrinology Business Development until the acquisition by Shire Pharmaceuticals for $5.2 billion in 2015.

Prior to NPS, Rae held the role of chief business officer at Arrowhead Research and Vivaldi Biosciences, as well as senior leadership roles at VIA Pharmaceuticals Inc (OTCMKS:VIAP), Purdue Pharma and Hoffman-La Roche, according to the statement.

Rae was an attorney specializing in biopharmaceutical intellectual property law and earlier in his career was a research scientist focusing on metastasis and the molecular basis of cellular transformation, the company said.  

CytoDyn said Bitar will be responsible for overseeing all facets of the company’s quality systems, quality assurance, and compliance operations to ensure that the product is manufactured consistently to meet FDA standards.

READ: CytoDyn secures fast track FDA designation for leronlimab in treating metastatic triple negative breast cancer

As CytoDyn enters into a new era of manufacturing partnerships with contract manufacturing organizations (CMOs) in preparation for post-approval product launch of leronlimab, a knowledgeable head of quality is a critical component of the approval and the commercialization process, the company said.

Bitar brings over 25 years in quality management, technical operations, pharmaceutical manufacturing and R&D, to CytoDyn, most recently as the global head of quality at Hitachi Chemical Advanced Therapeutics Solutions, a cellular and gene therapy contract development and manufacturing organization.

Previously, Bitar led Pfizer’s (NYSE:PFE) generic oncology and biosimilars manufacturing through the approval process and was the site head of quality for Pfizer’s specialty injectable and biologic drug products.

Prior to Pfizer, Bitar was vice President – head of quality at InnoPharma Inc., which was acquired by Pfizer.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full CYDY profile View Profile

CytoDyn Timeline

Related Articles

skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Enzymes under a microscope
April 28 2019
The Florida company applies its proprietary C1 gene expression platform to speed up the development of biologic vaccines, drugs at flexible commercial scales
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use